The Fuenzalida-Palacios rabies vaccine has been used in South America for rabies post-exposure prophylaxis. To determine the frequency of adverse reactions associated with this vaccine compared to a control group a quasi-experimental study was carried out in Uberlândia, Brazil, from May 1997 to April 1998 
Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study Reações Rabies remains an important health problem in the tropics, where it is mostly associated with bites from dogs and, to a lesser extent, other mammals, including bats. Rabies is almost invariably fatal, but can be prevented by post-exposure prophylaxis with rabies vaccine and antirabies serum. Pre-exposure rabies vaccination has been indicated only for professionals who are considered to be at high risk of acquiring rabies, such as veterinarians, mammal biologists, and dog catchers.
Several types of rabies vaccine have been used since Pasteur developed the first one over a century ago, using viruses that were maintained through multiple passages in rabbit spinal cord and inactivated by drying 9 12 . Diploid cell vaccines are presently considered the best rabies vaccines taking into account their high efficacy and low incidence of adverse reactions, but they are expensive and seldom available in developing countries. In South America, Fuenzalida-Palacios rabies vaccine 3 , which uses inactivated viruses prepared from suckling mouse brains, has been used for decades as an acceptable alternative to diploid cell vaccine given its comparable efficacy (although requiring a higher number of doses) and much lower cost. The drawback of nerve tissue-containing vaccines is the risk of neuroparalytic adverse reactions that is associated with them. The incidence of neurological complications was 1/200 (7 out of 1,392) in adults who received a Semple-type phenol inactivated lamb nerve tissue vaccine in Tunisia; these manifestations occurred a median of 11 days after the first vaccine injection 2 . These events are rarer for the Fuenzalida-Palacios vaccine, which by using suckling mouse brain as substrate has a decreased myelin content. The incidence of neuroparalytic reactions associated with this vaccine in a Mexican series was 27.6 per million doses 9 . More recent figures from the Brazilian literature for the state of São Paulo range from rates of 1:3,263 (1997) 11 to 1:34,533 (1980-1990) 5 . A retrospective study from Osasco, in São Paulo state, detected one neurological complication in 8,758 individuals submitted to post-exposure prophylaxis 5 . Notwithstanding their rarity, a few cases of neurological adverse reactions are expected to occur given the large number of individuals who require post-exposure rabies prophylaxis, over 280,000 per year in Latin America 1 . Surprisingly very little has been published on Fuenzalida-Palacios rabies vaccine-associated adverse reactions other than its neurotoxicity. Data from Latin America reveal that erythema, urticaria/pruritus, and lymphadenopathy occur respectively in 2/3, 1/3 and 1/4 of the individuals who are vaccinated 9 . A study from Nigeria, on the other hand, reported an incidence of 11.1% of local reactions and of 2.5% generalised reactions among individuals who received a suckling mouse brain vaccine 6 . The scarcity of data was the motivation for the undertaking of this study, the aim of which was to assess the incidence of adverse reactions associated with a Fuenzalida-Palacios rabies vaccine.
PATIENTS AND METHODS
A clinical trial with patients receiving or not rabies vaccine at random would be unethical. We took advantage of the fact that the Brazilian Ministry of Health's guidelines recommend post-exposure (FuenzalidaPalacios) rabies vaccine only to certain types of wounds and in certain circumstances 4 to design instead a quasi-experimental study 8 10 13 . In this design, a cohort of individuals injured (usually bitten) by dogs and other mammals was followed up over time and the occurrence of a number of symptoms was compared between those who were given post-exposure rabies vaccine and those who were not. The criteria for vaccine administration were those of the Brazilian Ministry of Health 4 . The rabies vaccine used throughout the study was manufactured by the Instituto de Tecnologia do Paraná (TECPAR), Curitiba, Brazil.
Face-to-face or telephone interviews were carried out by trained interviewers 10 to 15 days, and then 30 to 40 days after the injury (animal bite). In these interviews questions were asked to the participants or caregivers about the occurrence of symptoms that included those already expected to be associated with FuenzalidaPalacios rabies vaccine, and also others that were unlikely to be associated with it. The latter were included in the questionnaire to assess the possible occurrence of information bias 8 . The finding of several clinical manifestations to be more common among individuals who were vaccinated, including some unlikely to be associated with the vaccine, would suggest that those who received the vaccine were over-reporting symptoms.
The sample size calculation took into account previous data that indicated that about 2,400 (200 per month) individuals could be expected to be injured by mammals in Uberlândia in a period of 12 months, and that about 40 percent of them would require post-exposure rabies prophylaxis. This sample size of 2,400 would have a power of 80 percent to detect risk ratios of 2.7 and 6.5 for incidences of clinical manifestations of respectively 10 per 1,000 and 2 per 1,000 among the individuals who did not receive the vaccine. In the statistical analysis, comparisons between continuous variables were made with the t test. Comparisons of the incidences of symptoms between the two groups were made by the calculation of risk ratios (RR) with 95% confidence intervals, and by significance tests (chi square or Fisher's exact test, wherever appropriate). The EpiInfo package (Centers for Disease Control, Atlanta, GA), version 6.04b, was used for the statistical analysis.
RESUL TS
A total of 2,440 individuals injured by dogs and other mammals were attended at the Unidade Básica de Saúde Fausto Savastano, Uberlândia's reference centre for rabies prophylaxis, from 1 May 1997 to 30 April 1998. All patients had their baseline data registered, except 326 who were excluded from the study because their charts were incomplete. Out of the remaining 2,114 individuals, 1,684 (79.7%) received rabies vaccine whereas 430 (20.3%) did not. Age and sex distribution did not differ between the two groups. Only 55 (3.3%) of the patients who were vaccinated also received antirabies serum. The number of individuals who answered the questionnaire between the 10 th and 15 th days after the injury, and between the 30 th and 40 th days were, respectively, 1,004 (47.5%) and 542 (25.6%).
The incidences of symptoms among the individuals who received the vaccine are shown in Table 1 . Headache and pain at the injection sites were reported most frequently, with an incidence of around 125 per 1,000 individuals within 10 to 15 days after the start of the vaccination schedule.
Bonito RF et al No case of neuroparalytic accident was detected through the interviews. Only one patient had a skin rash classified as severe but that responded well to oral chlorpheniramine. The risk ratios of certain signs and symptoms among individuals who received or not Fuenzalida rabies vaccine were generally close to 1, with 95% confidence intervals including the unit (Table 2 ). Only the incidence of one symptom (toothache during the first 10 to15 days) was significantly different between the two groups, and was higher among the individuals who were not vaccinated.
DISCUSSION
Although the Fuenzalida-Palacios rabies vaccine has been used in South American countries since the 1960s, very little is available in the literature about the incidence of associated adverse reactions. Even the reports of severe adverse reactions that can be either life-threatening or lead to permanent disability, such as neuroparalytic accidents, are few, and a detailed analysis of a causal relationship is not available.
The findings of this study suggest that Fuenzalida-Palacios rabies vaccine is safe, based on the absence of detection of severe adverse reactions. This study had a sample size that was insufficient for the detection of relative risks of low magnitude. Nevertheless it is unlikely that lack of statistical power explained the failure to detect more common adverse reactions, given that the risk ratio estimates were close to 1 and the confidence intervals relatively narrow. Bias due to nonparticipation could be a concern giving the low proportion of participants in the study who responded to the follow-up interviews. However, if participation varies according to likelihood of exposure but not disease then the risk ratio is not biased 7 . Information bias is unlikely to have occurred as no trend suggestive of over-or underreporting of symptoms in any of the two groups of patients was detected. At least for neuroparalytic accidents it is very unlikely that underreporting has occurred, giving that cases which could be missed in the study should have been detected by the surveillance system existent in the Uberlândia region because of the program for poliomyelitis elimination, and none was notified. The finding that toothache was more common among individuals who were not vaccinated was most probably due to chance, given the large number of comparisons made. Although randomisation was not undertaken in this study, the allocation of patients to receive or not rabies vaccine was quasi-experimental, and therefore confounding factors should not be expected to threaten the validity of the findings.
